Document 993GYqodGBg81dkJrdaq7KEX5
(SPF Sant Publique - FOD Volksgezondheid)
From: Sent: To:
Subject: Attachments:
(SPF Sant Publique - FOD Volksgezondheid) mercredi, 23 novembre 2022 16:24
(SPF Sant Publique - FOD Volksgezondheid); Publique - FOD Volksgezondheid) RE: Meeting request - Zoetis Europe pfas-position-_-efpia-and-animalhealtheurope-january-2022.pdf
(SPF Sant
Hi,
"Hydrofluorocarbons act as safe propellants to aerosolize the active pharmaceutical ingredients (API) and ensure the delivery the of the medicine to the lungs"
Zie bijlage voor meer info. (en om ons voor te bereiden op hun komst )
Hieruit blijkt dat PFAS in een hele range in de pharma industrie wordt gebruikt: 1) Active Pharmaceutical Ingredients 2) Starting Materials and Chemical Intermediates 3) Auxiliaries and Production Material 4) Synthetic and Analytical Reagents 5) Primary Packaging Materials 6) Medical Devices
Groetjes,
DG Environment | Department of Product Policy and Chemicals Galileelaan, 5/2 | 1210 Bruss | Belgium
www.health.belgium.be | Contact Center +32 (0)2.524.97.97
Spaar onze natuurlijke hulpbronnen door dit e-mailbericht niet nutteloos af te drukken.
Van:
(SPF Sant Publique - FOD Volksgezondheid) < . @health.fgov.be>
Verzonden: woensdag, 23 november 2022 16:10
Aan:
(SPF Sant Publique - FOD Volksgezondheid) < .
@health.fgov.be>;
(SPF
Sant Publique - FOD Volksgezondheid) < .
@health.fgov.be>
Onderwerp: RE: Meeting request - Zoetis Europe
Bonjour ,
1
Non je n'ai pas de connaissance de a. C'est possible que des F-gasses sont prsent, mais je n'ai pas sr.
There are PFAS present in some human pharmaceuticals so maybe something like this? It would nonetheless be interesting to have them present something for more info.
Cheers,
Van:
(SPF Sant Publique - F0D Volksgezondheid) <ffl.
Verzonden: mardi, 22 novembre 2022 15:10
Aan:
(SPF Sant Publique - F0D Volksgezondheid)
Publique - F0D Volksgezondheid) <
.ffl@health.fgov be>
Onderwerp: RE: Meeting request -- Zoetis Europe
@health.fgov.be> @health.fgov.be>;
Savez-vous s'il s'agit de PFAS dans des arosols qui sont directement inhals par les animaux ?
(SPF Sant
From:
(SPF Sant Publique - F0D Volksgezondheid)
@health.fgov.be>
Sent: mardi, 22 novembre 2022 13:47
To:
(SPF Sant Publique - F0D Volksgezondheid) <
@health.fgov.be>;
(SPF Sant Publique - F0D
Volksgezondheid) <
.ffl@health.fgov.be>
Cc:
(SPF Sant Publique - F0D Volksgezondheid) <ffl.
@health.fgov be>
Subject: RE: Meeting request -- Zoetis Europe
Moesten ze een meeting willen plannen, ben ik wel genteresseerd om mee te volgen. Een paar maanden geleden heb ik een AfA dossier van hun behandelt.
DG Environment I Department of Product Policy and Chemicals Galileelaan, 5/2 l 1210 Bruss I Belgium
r
federale overheidsdienst
VOLKSGEZONDHEID, VEILIGHEID VAN DE VOEDSELKETEN EN LEEFMILIEU
www.health.belgium.be I Contact Center +32 (0)2.524.97.97
db. be l e Spaar onze natuurlijke hulpbronnen door dit e-mailbericht niet nutteloos of te drukken.
Van: Reach (SPF Sant Publique - F0D Volksgezondheid) <
@health.fgov.be>
Verzonden: dinsdag, 22 november 2022 13:31
Aan:
(SPF Sant Publique - F0D Volksgezondheid) <
ffl @heaIth.fgov.be>
CC:
(SPF Sant Publique - F0D Volksgezondheid) <ffl.
@health.fgoy.be>;
Publique - F0D Volksgezondheid)
@health.fgov.be>
Onderwerp: TR: Meeting request -- Zoetis Europe
2
(SPF Sant
Geen info van hun
De :
- Belgium - Bruss EU < .
@diplobel.fed.be>
Envoy : mardi, 25 octobre 2022 20:24
:
@zoetis.com>
Cc :
@hanovercomms.com>;
(SPF Sant Publique - FOD Volksgezondheid)
< @health.fgov.be>
Objet : RE: Meeting request - Zoetis Europe
Dear
,
Thank you for your email and all the information you provided.
Given the high complexity and technicality of this dossier and the fact that it is not a legislative dossier as such, I kindly ask you to address your request to our Belgian Reach Committee (the contact address is copied in this e-mail). You will have the opportunity, with the agreement of the Chair, to present your industry and your opinion/concerns in front of a panel of experts (which I think is more interesting).
Best regards,
Permanent Representation of Belgium to the European Union Rue Belliard 65, B-1040 Bruss
@diplobel.fed.be
europeanunion.diplomatie.belgium.be
De :
@zoetis.com>
Envoy : jeudi 20 octobre 2022 15:47
:
- Belgium - Bruss EU < .
@diplobel.fed.be>
Cc :
@hanovercomms.com>
Objet : Meeting request - Zoetis Europe
Dear Mr.
,
I hope you are well.
I am writing to request a meeting the week of 7 November or thereafter to discuss an important regulatory issue that will significantly impact on innovation and the competitiveness of the European animal health sector, and on production of leading veterinary medicine products in Belgium.
Member State regulators and the European Commission are planning to restrict the use of per- and polyfluoroalkyl (PFAS) substances in most products. The restriction proposal will come soon and will have serious impacts on the animal health sector. A ban on PFAS use would remove best-in-class animal medicines from the EU market and restrict the availability of inhalation anaesthetics that are used in complex surgeries in humans and animals. A restriction would also affect manufacturing of animal health products in Europe for local use and for export. It would also restrict the ability to meet the objectives of the EU Pharmaceutical Strategy.
We would appreciate the opportunity to sit down with you to discuss Zoetis' role as a global market leader in animal medicines innovation, and outline how veterinary medicinal products and industrial emissions from production in our
3
sector are strictly regulated in the EU to ensure human, animal and environmental health and safety. Given the public attention on PFAS at present, we believe a discussion on the use of PFAS in animal medicines and the low exposure pathways from this use is warranted to understand the need for exemptions for animal medicines.
meeting.
( at Zoetis and
in the AnimalHealthEurope Working Group on PFAS) and I would join the
We look for to hearing from you and remain at your disposal for any questions you have.
With kind regards,
@zoetis.com| Mercuriusstraat 20, 1930 Zaventem, Belgium | www.zoetis.com
LEGAL NOTICE Unless expressly stated otherwise, this message is confidential and may be privileged. It is intended for the addressee(s) only. Access to this e-mail by anyone e is unauthorised. If you are not an addressee, any disclosure or copying of the contents of this e-mail or any action taken (or not taken) in reliance on it is unauthorised and may be unlawful. If you are not an addressee, please inform the sender immediately. Zoetis Belgium sa is registered in Belgium under TVA BE 0401 953 350 with its registered office at Rue Laid Burniat 1, 1348 Louvain-La-Neuve, Belgium.
4